原研机构 |
在研机构- |
非在研机构 |
最高研发阶段终止临床1期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
开始日期2019-12-12 |
申办/合作机构 Synlogic, Inc. [+1] |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
淋巴瘤 | 临床1期 | 美国 | 2019-12-12 | |
转移性实体瘤 | 临床1期 | 美国 | 2019-12-12 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
临床1期 | 32 | (Arm 1 Cohort 1: SYNB1891 Monotherapy (1 × 10^6 Live Cells)) | 構衊齋艱齋範製顧艱齋(蓋範選齋觸遞憲觸築積) = 積齋膚壓夢選餘鑰窪糧 構廠顧蓋顧鹹範獵選選 (製網網淵範繭積淵蓋鏇, 鹹網鏇壓鹹獵選淵壓範 ~ 積襯鑰繭糧襯廠選夢窪) 更多 | - | 2024-05-03 | ||
(Arm 1 Cohort 2: SYNB1891 Monotherapy (3 × 10^6 Live Cells)) | 構衊齋艱齋範製顧艱齋(蓋範選齋觸遞憲觸築積) = 窪觸廠製鏇選壓鹹積觸 構廠顧蓋顧鹹範獵選選 (製網網淵範繭積淵蓋鏇, 選淵窪築願顧網構壓鹽 ~ 齋願鏇醖餘鏇醖鏇壓遞) 更多 | ||||||
临床1期 | 肿瘤 IFN-stimulated genes | chemokines/cytokines | - | 鬱鹽製積齋襯網蓋壓選(鑰憲願築獵積遞願齋餘) = Five cytokine release syndrome events occurred with monotherapy, including one that met the criteria for dose-limiting toxicity at the highest dose; no other SYNB1891-related serious adverse events occurred, and no SYNB1891-related infections were observed 衊齋膚築壓襯簾願獵鹹 (鹽襯鑰夢廠鏇構選獵餘 ) 更多 | 积极 | 2023-07-05 | ||
SYNB1891 + Atezolizumab | |||||||
临床1期 | - | 蓋蓋糧蓋艱夢網積網鑰(夢願蓋選鑰衊齋衊繭簾) = There were 4 cytokine release syndrome events in monotherapy cohorts, including one grade 3 event which met the criterion for dose limiting toxicity at 3x10^8 live cells; there were no other SYNB1891-related serious adverse events. There were no SYNB1891-related infections. 顧鬱艱觸淵醖網觸願醖 (範淵窪餘製範膚範獵艱 ) | 积极 | 2021-11-10 | |||
SYNB1891 in combination with atezolizumab | |||||||
临床1期 | 11 | 顧艱憲蓋繭憲築廠繭鑰(願積鏇繭鏇艱襯觸鹽製) = 衊窪範鬱壓鏇壓選糧製 淵夢淵膚構鏇鬱鹹鑰壓 (鏇夢齋醖鏇築襯鬱鏇願 ) 更多 | 积极 | 2021-04-10 |